FDA approves this nasal spray to treat depression, could help those who have no success with available treatments

There are about 16.2 million Americans who suffer from major depression, and as many as a quarter of them reported achieving little to no results from available treatments, including drugs and therapy. This week, the U.S. Food & Drug Administration approved esketamine, a fast-acting drug derived from the anesthetic, ketamine, that is intended to aid the
Read more → Read more here >>>

thumbnail courtesy of positiveoutlooksblog.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here